Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.48 |
| ▸ | SMO | Q99835 | 14/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243273 | 0.84 | MAPK14 (0.48) | MAPK14SMO | |
| SCHEMBL243811 | 0.76 | MAPK14 (0.52) | MAPK14SMO | |
| SCHEMBL243760 | 0.72 | MAPK14 (0.56) | MAPK14SMO | |
| SCHEMBL2904915 | 0.72 | MAPK14 (0.52) | MAPK14SMO | |
| SCHEMBL243467 | 0.71 | MAPK14 (0.50) | MAPK14SMO | |
| SCHEMBL1901397 | 0.71 | MAPK14 (0.53) | MAPK14SMO | |
| SCHEMBL243419 | 0.70 | MAPK14 (0.54) | MAPK14SMO | |
| SCHEMBL244357 | 0.70 | MAPK14 (0.52) | MAPK14SMO | |
| Bromide SCHEMBL241935 | 0.70 | MAPK14 (0.52) | MAPK14SMO | |
| SCHEMBL3649540 | 0.70 | SMO (0.77) | MAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943776-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | MAPK14 1549/4885SMO 2872/4885CACNA1H 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.